Interventions to reduce opioid use for patients with chronic non-cancer pain in

- 2 primary care settings: a systematic review and meta-analysis.
- ¹Qian Cai*, ²Christos Grigoroglou, ²Thomas Allen, ³Teng-Chou Chen, ³Li-Chia Chen,
- 4 ^{1,4}Evangelos Kontopantelis

1

5

- 6 ¹ Division of Informatics, Imaging & Data Sciences, School of Health Sciences,
- 7 Faculty of Biology, Medicine and Health, Manch6ester Academic Health Science
- 8 Centre, University of Manchester, Manchester, the United Kingdom.
- 9 ² Centre for Health Economics, Division of Population Health, Health Services
- 10 Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine
- 11 and Health, Manchester Academic Health Science Centre, University of Manchester,
- 12 Manchester, the United Kingdom
- 13 ³ Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and
- 14 Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health,
- 15 University of Manchester, Manchester, the United Kingdom.
- 16 4 National Institute for Health and Care Research (NIHR) School for Primary Care
- 17 Research, Division of Population Health, Health Services Research and Primary
- 18 Care, School of Health Sciences, Faculty of Biology, Medicine and Health,
- 19 Manchester Academic Health Science Centre, University of Manchester, Manchester,
- 20 the United Kingdom.
- 22 *Corresponding author:
- 23 Qian Cai

- 24 Division of Informatics, Imaging & Data Sciences, School of Health Sciences, Faculty
- 25 of Biology, Medicine, and Health, University of Manchester, Manchester, M13 9PL,
- 26 the United Kingdom
- 27 Phone: (0)7419737634
- 28 Email: qian.cai@manchester.ac.uk

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Abstract Objective: This systematic review and meta-analysis aimed to assess interventions to reduce opioid use for patients with chronic non-cancer pain (CNCP) versus usual care or active controls in primary care settings. Methods: In this registered study (PROSPERO: CRD42022338458), we searched MEDLINE, Embase PsycInfo, CINAHL, and Cochrane Library from inception to December 28th 2021, and updated on Dec 14th 2023 for randomized controlled trials (RCTs) and cohort studies with no restrictions. Methodological quality was assessed using the Cochrane Risk of Bias tool for RCTs and Newcastle Ottawa Scale for cohort studies. Primary outcomes included mean reduction in morphine equivalent daily dose (reported as mean differences [MDs] mg/day; 95% confidence intervals [95%Cls]) and/or opioid cessation proportion. Secondary outcomes were mean changes in pain severity (reported as standardized mean difference [SMDs]; 95%Cls) and (serious) adverse events. Meta-analyses were performed using random-effects models. **Results:** We identified 3,826 records, of which five RCTs (953 participants) and six cohort studies (967 participants) were included. Overall, opioid dosage was significantly reduced in intervention groups compared to controls (MD: -24.88 mg/day, 95%CI: -36.40 to -13.36; $I^2=59.41\%$; nine studies). Subgroup analyses revealed significant opioid dose reductions with mindfulness (MD: -29.36 mg/day 95%CI: -40.55 to -18.17; I^2 =0.0%; two trials) and CBT-based multimodalities (MD: -41.68 mg/day; 95%CI: -58.47 to -24.89; I^2 =0.0%; two cohort studies), respectively, compared to usual care. No significant differences were observed in opioid cessation (Odds ratio: 1.55, 95%CI: 0.3 to 2.81, I^2 =50.79%; three studies) or pain severity (SMD: -0.13, 95%CI: -0.37 to 0.11; $I^2=33.51\%$; three trials). Adverse events were infrequently examined, with withdrawal symptoms commonly reported. **Conclusions:** The studied interventions were effective in reducing opioid dosage for people with CNCP in primary care. They highlighted the importance

multidisciplinary collaboration. Large-scale RCTs measuring the long-term effects and cost of these interventions are needed before their implementation.

Introduction

Opioids are primarily recommended by the World Health Organization pain ladder in treating acute pain, cancer pain, and palliative care [1]. During the last two decades, there has been a marked increase in opioid prescriptions issued for chronic non-cancer pain (CNCP), predominantly in the United States (US) [2], Canada [3], and several European countries [4-6] including the United Kingdom (UK) [7]. Despite the widespread utilization of opioids, findings from randomized controlled trials and systematic reviews suggest limited efficacy of these medications, yielding only modest effects in pain relief in the short to medium term (less than 12 weeks) [8]. While the evidence supporting the long-term use of opioids remains sparse, the associated harms of long-term opioid treatment (LTOT), including respiratory depression, bone fractures, and opioid-related mortality, are well documented [9]. Moreover, prolonged opioid use introduces risks of dependence, addiction, and abuse [10].

In response to these concerns, clinical guidelines [11-13] have prompted healthcare providers (HCPs) to reassess their prescribing practices, emphasizing the need to reduce opioid use when potential risks outweigh perceived benefits. However, the endeavor to reduce opioid use encounters significant challenges, including patients' fear of withdrawal symptoms, inadequate social and healthcare support, and limited availability of non-opioid methods for pain management [14, 15]. Currently, there is a lack of guidance and practical support to implement the reduction of LTOT. Therefore, there is an urgent need for an evidence-based evaluation of interventions to assess their effectiveness in reducing opioid utilization and evaluate their impact on clinical outcomes, particularly in primary care settings, where opioids are mostly prescribed.

Previous systematic reviews [16-19] have provided valuable insights into interventions aimed at reducing opioid use for chronic pain patients. However, their inclusion criteria were broad, limiting their relevance to primary care settings. For example, these reviews analyzed interventions (e.g., spinal cord stimulation) that are not readily accessible in primary care settings, and they included studies that evaluated abrupt or gradual opioid tapering protocols without incorporating additional supportive therapies for patients. The provision of supplementary interventions is crucial, as patients often express reluctance to reduce or cease opioids when alternative treatments are not provided, given these medications constitute their primary method of pain management in real-world practices. Furthermore, the absence of additional interventions impedes the identification of the key components contributing to the dose reduction outcomes. Some prior systematic reviews also included pilot studies lacking clear objectives of opioid reduction. This is particularly common for studies using pharmacological substitution, where the primary aim was to address opioid withdrawal symptoms rather than reducing opioid dosage, despite achieving a decrease in opioid dosage or an improvement in pain severity. In view of these limitations and the emergence of new studies recently, there is a compelling need for an updated evaluation of the current evidence.

The present systematic review and meta-analysis aimed to evaluate the effectiveness of healthcare provider-directed interventions designed to reduce or discontinue opioid use for patients with CNCP, with a particular focus on primary care settings. Specifically, the objectives included comparing changes in morphine equivalent daily dose (MEDD), evaluating the proportion of patients discontinuing opioids, and assessing the change in pain severity and adverse events between interventions and usual care or active controls.

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

Methods This registered systematic review and meta-analysis (PROSPERO: CRD42022338458) was conducted following the Cochrane Handbook [20] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1 Appendix) [21]. Eligibility criteria Eligible studies were full-scale randomized controlled trials (RCTs) and cohort studies that examined primary care provider-directed interventions, designed to reduce or discontinue opioids in adult patients (≥18 years) with CNCP (persists for ≥3 months). Studies that concurrently used opioids with other analgesics (e.g., non-steroidal antiinflammatory drugs) were excluded, as distinguishing the analgesic effects of opioids from those analgesics were challenging. Interventions implemented in hospital settings or managed by patient themselves were not considered for inclusion. Studies that solely focused on reducing opioids without offering patients alternate treatments or replacements were excluded. Interventions were considered if they explicitly aiming to reduce or cease opioid use, whereas those with a spillover effect on opioid use were excluded. Any comparator was accepted, including usual care or active controls (either pharmacological or non-pharmacological). The primary outcomes of interest included: 1) opioid dose reduction, measured by the mean changes in morphine milligram equivalent daily dose (MEDD) from pre- to post-treatment. The homogeneity of this outcome measure allowed us to examine our study objectives meta-analytically; 2) The proportion of participants for whom opioid use was either ceased or declined. Secondary outcomes included the mean change in pain severity (measured by pain rating scales on a range of 0-10, where 0 indicating no pain whilst 10 indicating severe pain) and the number of (serious) adverse events related to opioid reduction. Case reports, cross-sectional studies,

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

case-control studies, pilot studies, reviews or meta-analyses were excluded. Data sources and search strategies We performed comprehensive searches in databases including MEDLINE, EMBASE, PsycINFO, CINAHL, and Cochrane Central Register of Controlled Trials. Searches were conducted from the inception of each database until December 28th 2021, and updated on December 14th 2023, using structured search strategies (S2 Appendix) that incorporated text words and medical subject headings related to "chronic pain", "opioids", and "reduce/discontinue/cease/deprescribe/". No language and geographic restrictions were applied. Ongoing trials or unpublished studies were obtained from ClinicalTrials.gov. To ensure literature saturation, we manually retrieved additional studies from the reference lists of included studies and published systematic reviews. Study selection Two review authors (QC and CG) independently screened titles and abstracts of the retrieved citations against pre-determined inclusion/exclusion criteria. When necessary, full text of eligible records were reviewed for further eligibility assessment. Where discrepancies occurred and remained unresolved by discussion, a third party (EK, TA and LCC) was consulted for adjudication. The inter-rater agreement test demonstrated a high level of consistency (99.64%) between QC and CG with a Kappa coefficient equals to 0.7982 (p<0.001). Data extraction and quality assessment Data extraction was undertaken independently by one review author (QC) and verified by another reviewer (TCC) for accuracy. The study authors were also contacted by email to request any necessary missing information. The following key information was extracted:

Study: first author, publication year, country, study design, settings.

- Patient characteristics: age, gender, sample size, pain duration and severity,
 opioid use status, comorbidities.
- Intervention and comparator: key components, mode of administration,
 frequency, treatment duration.
 - Outcome: opioid dose, pain severity, adverse events.

Risk of bias assessment

The methodological quality of all included studies was independently appraised by QC. For RCTs, the Cohrane's Risk of Bias Tool 2.0 (RoB 2) [22] was employed to assess the risk of bias, including 1. sequence generation; 2. allocation concealment; 3. masking of participants, staff and outcome assessors; 4. incomplete outcome data; and 5. selective outcome reporting. For cohort studies, a modified Newcastle-Ottawa Scale (NOS) [23] was used to evaluate bias risk, focusing on 1. the representativeness of the exposed cohort; 2. selection of the non-exposed cohort; 3. ascertainment of exposure; 4. absence of the outcome of interest at the start of the study; 5. comparable controls; 6. assessment of outcome; 7. sufficient follow-up length for outcomes to occur; and 8. adequacy of follow-up cohorts. For RCTs, high quality was defined as minimum 4 domains of low risk. As for cohort studies, the modified NOS adopted a star rating system. A study was deemed to be of good quality if it obtained ≥3 stars in selection domain (1-4), ≥1 star in comparability domain (5), and ≥2 stars in outcome/exposure domain (6-8).

Data synthesis and analysis

The study characteristics and details of opioid reduction interventions were presented descriptively. Effect sizes were reported using odds ratios (ORs) with their 95% confidence intervals (95%Cls) for opioid cessation, mean differences (MDs) with 95%Cls for opioid dose reduction, and standardized mean differences (SMDs) with 95%Cls for pain severity, given the utilization of different scales for this outcome

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

measure. Magnitude of effect was defined as large (SMD > 0.8), medium (SMD 0.5-0.8), small (SMD 0.2-0.5) or trivial (SMD < 0.2) [24]. Where between- or within-group SDs were not reported, relevant data such as sample size, p values, t statistics, standard errors (SEs), or 95% CIs were used to derive SDs using the formula recommended by the Cochrane Handbook (6.5.2.3) [20] or the calculator embedded in Review Manager 5.4. Additionally, when outcomes were assessed at multiple time points during long-term follow-up, data from the last available time point were employed. Heterogeneity was assessed using the I² statistics, with values below 50% suggesting low heterogeneity, 50-75% moderate, above 75% substantial heterogeneity [25]. Random effects meta-analyses with a non-parametric bootstrap of DerSimonian Laird (DL) method were conducted for pooling the outcomes of interest [26, 27] even if I² was low. Publication bias regarding the primary outcomes was not assessed due to the small number of included studies. Sensitivity analyses were conducted by sequentially removing one study at a time and repeating the meta-analysis based on the remaining data to assess whether pooled estimates were unduly influenced by specific studies. Furthermore, multivariable random effects meta-regressions were conducted to explore potential sources of heterogeneity, including patient mean age; gender; study period; sample size; follow-up time point; intervention type and category. Subgroup analyses were undertaken based on intervention types, which included mindfulness techniques, and CBT-based multi-component strategies. All data analyses were conducted with Stata/MP 17.0.

Results

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

Study selection and patient characteristics

The initial search retrieved 3,826 potentially relevant records, of which 1,126 duplicates were removed, yielding 2,770 unique records for eligibility assessment. By screening titles and abstracts against our predefined inclusion/exclusion criteria, 2739 studies were excluded. Of the remaining 31 records, eleven full-text articles including five RCTs (953 participants, female 557 [58.4%], mean age: 60.1±13.42) [28-32] and six retrospective cohort studies (patients 967, female 214 [22.1%], mean age: 54.2±13.52) [33-38] published between 2016 and 2023 were included in this systematic review and meta-analysis (Fig 1. Selection of included studies). All included studies reported the baseline opioid dosage (mean 87.4±131.8 mg/day), with three [31, 33, 37] indicating that participants consumed a mean MEDD of >120 mg/day. Most studies did not specify the exact CNCP conditions, except for one study that explicitly mentioned chronic musculoskeletal pain [38]. Studies were mainly conducted in the US (n=10), with one in the UK [30]. Both RCTs and retrospective cohort studies had a small sample size ranging between 35 and 608 (Table 1).

Table 1. Characteristics of included studies

Author, year and country	Study design	Population	interventions	Comparators	Outcomes of interest assessed	Quality
Randomized contr	rolled trials (n=5)					
Sandhu <i>et al.</i> 2023 [30], UK	Non-blind, two-arm, RCT	CNCP (n=608) female 362 (60%)	Skill-based learning integrating education and mindfulness (n=305)	Usual care (n=303)	 Opioid cessation Pain severity Adverse events	Good
Wartko <i>et al.</i> 2023 [32], USA	Non-blind, two-arm, RCT	CNCP (n=153) female 98 (64%)	CBT-based pain coping skills training, education and usual care (n=79)	Usual care (n=74)	 Opioid dose reduction Pain severity Adverse events	Good
Hudak <i>et al.</i> 2021 [29], USA	Non-blind, two-arm, RCT	CNCP (n=62) female 9 (14.5%)	The MORE protocol: Mindfulness (n=34)	The supportive care (n=28)	Opioid dose reduction	Good
Garland <i>et al.</i> 2020 [28], USA	Non-blind, two-arm, RCT	CNCP (n=95) female 63 (66.3%)	The MORE protocol: Mindfulness (n=50)	The supportive care (n=45)	Opioid dose reduction	Fair
Sullivan <i>et al.</i> 2017 [31], USA	Non-blind, two-arm, RCT	CNCP (n=35) female 25 (71.4%)	CBT-based multimodality & self- care & pain education (n=18)	Standard of care (n=17)	 Opioid dose reduction Opioid cessation Pain severity	Fair
Cohort studies (n=	=6)				•	
Montgomery et al. 2020 [35], USA	Retrospective cohort study	CNCP (n=47) female 5 (10.6%)	Acupuncture (n=24)	Standard of care (n=23)	 Opioid dose reduction Pain severity	Poor
Seal <i>et al.</i> 2019 [37], USA	Retrospective cohort study	CNCP (n=294) female 30 (10.2%)	Integrated multimodality including CBT, mindfulness, pain education, acupuncture and exercise (n=147)	Standard of care (n=147)	Opioid dose reduction	Good
Oldfield <i>et al.</i> 2018 [36], USA	Retrospective cohort study	CNCP (n=105) female 7 (6.7%)	Multimodality integrating CBT, exercise, and acupuncture (n=66)	Standard of care (n=39)	Opioid dose reduction	Good
Goodman <i>et al.</i> 2018 [33], USA	Retrospective cohort study	CNCP (n=41) female 22 (53.7%)	Opioid reduction program & consultation with GPs (n=27)	Usual care (n=14)	Opioid dose reduction	Fair

Author, year and country	Study design	Population	interventions	Comparators	Outcomes of interest assessed	Quality
Vigil <i>et al.</i> 2017 [38], USA	Retrospective cohort study	CMSK (n=66) female 26 (39.4%)	Medical cannabis & patient education (n=37)	Patient education (n=29)	 Opioid dose reduction Opioid cessation Pain severity	Fair
Mehl-Madrona <i>et al.</i> 2016 [34], USA	Retrospective cohort study	CNCP (n=414) female 124 (59.9%)	Medical care and physical exercise (n=207)	Standard of care (n=207)	Opioid dose reduction	Good

Note: CNCP=Chronic Non-Cancer Pain, CMSK=Chronic Musculoskeletal Pain, MORE=Mindfulness-Oriented Recovery Enhancement, CBT=Cognitive Behavioral Therapy, GPs=general practitioner

240

Characteristics of interventions

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

The components, duration, frequency, and delivery mode of the interventions varied significantly across studies. One study used medicine substitution approach, transitioning opioids to cannabis [38]; Two studies focused on physical interventions, incorporating components such as yoga, Taichi, chiropractic therapy [34] and acupuncture [35]; Five studies involved psychological or behavioral changes, integreting key components such as cognitive behavior therapy (CBT), mindfulness techniques, patient education and pain coping skills training [28-30, 32, 33]; Three studies [31, 36, 37] employed mixed multimodal approaches delivered by a multidisciplinary team comprising physicians, nurses, psychologists, pharmacists, and social workers. These multimodal care programs typically combined CBT, mindfulness, acupuncture, chiropractic care, exercise, pharmacotherapies are the core components. The most common comparator was usual care, with the exception of one study that used patient education as the comparison group [38]. Treatment durations ranged from eight weeks to 12 months. Follow-up periods (median 6 months) varied from short (≤3 months) [28, 29] to intermediate (6-9 months) [31, 33-37], with three studies reporting long-term outcomes of opioid reduction (≥12 months) . (See Table 2 for characteristics of interventions).

Table 2. The components and implementation procedures of each intervention

Studies	Interventions	Duration	Implemented by
Pharmacological substitution	(n=1)		
Vigil et al. 2017 [38]	Medical cannabis & patient education	21 months	Physicians
Physical procedure (n=2)			
Montgomery et al. 2020 [35]	Battlefield Acupuncture: 5-point auricular acupuncture procedure implemented	9 months	Physicians
Mehl-Madrona et al. 2016 [34]	Twice monthly GMV (12 sessions) & weekly physical activity (yoga, exercise class, chiropractic therapy, osteopathic treatment, tai chi, or qigong)	6 months	Family doctor, nurse, and behavioral health specialist
Psychological or behavioral in	tervention (n=5)		
Sandhu et al. 2023 [30]	Weekly skill-based learning and education including mindfulness, relaxation, opioid education, consultation and followed by an opioid taper (weekly 10% reduction)	12 months	Nurse
Wartko <i>et al.</i> 2023 [32]	CBT-based pain coping skill training: 18 sessions (30 min for each on average), mainly including pain education, goal setting, relaxation skills and motivational interviews, conducted over one year.	12 months	Primary care provider, nurse, physician assistant
Hudak et al. 2021 [29]	The MORE protocol: 2-hour weekly training sessions in mindfulness, reappraisal and savoring pleasant events & a 15-min CD-guided mindfulness practice at home and 3-minute breathing before taking opioids	4 months	Clinical social workers
Garland <i>et al.</i> 2020 [28]	The MORE protocol: 2-hour weekly training sessions in mindfulness, reappraisal and savoring pleasant events & a 15-min CD-guided mindfulness practice at home and 3-minute breathing before taking opioids	3 months	Clinical social workers
Goodman et al. 2018 [33]	Family physician-patient's discussion of pain management guidelines and practice followed by an opioid tapering program (weekly 10% reduction to 25%-50% reduction every few days)	6 months	Family physician
Multimodalities (n=3)			
Sullivan <i>et al.</i> 2017 [31]	A weekly 10% reduction of the initial dose until 30% was reached. Then, a 10% was recalculated based on this dose and then proceeded by 10% of this new dose per week.) & 17 weekly 30-min consultations, CBT-modelled pain self-management,	8.5 months	Pain medicine/psychiatry physicians, psychologists and physician assistants

Studies	Interventions	Duration	Implemented by
	education & a book/CD-guided home practice		
Oldfield et al. 2018 [36]	Multidisciplinary ORC program including pharmacotherapy, CBT and other modalities (e.g., acupuncture, chiropractic, and yoga)	6 months	Physicians, pain specialists, pain psychologists and chemical dependency counsellors
Seal et al. 2019 [37]	Integrated Pain Team: an initial 60-min's biopsychosocial model of pain management (including CBT, mindfulness, acupuncture, chiropractic care, and exercise) & a 30-min follow-up visits	6 months	Medical provider, psychologist, and pharmacist

Note: MORE=Mindfulness-Oriented Recovery Enhancement, CBT=Cognitive Behavioral Therapy, ORC=Opioid Reassessment Clinic, GMV=Group Medical Visits

Risk of bias assessment

The Cochrane RoB-2 assessment indicated an overall risk of bias being low (n=3) to moderate (n=2) (Fig 2. Risk of Bias of included RCTs). Due to the impossibility of masking the interventions, participants and researchers were unblinded, which increased risk. The high dropout rate during follow-ups was another main reason contributing to the increased risk of bias. The NOS evaluation tool identified three cohort studies [34, 36, 37] with good quality, two [33, 38] with fair and one [35] with poor quality (Table 3). Uncontrolled confounders and limited representativeness of the study population were the main reasons that reduced the quality of these studies.

Table 3. Quality assessment outcomes of cohort studies

	Three domains of the Newcastle-Ottawa Scale			
Author and year	Selection of participants	Comparability of study groups	Outcomes	Quality
Montgomery et al. 2020 [35]	***	*	*	Poor
Seal et al. 2019 [37]	***	**	***	Good
Oldfield et al. 2018 [36]	***	**	***	Good
Goodman et al. 2018 [33]	***	*	**	Fair
Vigil et al. 2017 [38]	***	*	**	Fair
Mehl-Madrona <i>et al.</i> 2016 [34]	***	**	***	Good

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

Opioid dose reduction Ten studies including four RCTs [28, 29, 31, 32] and six cohort studies [33-38] reported the outcomes of opioid dose reduction. Opioid dosage was significantly decreased in the intervention groups compared to controls (MD: -31.80 mg/day, 95%CI: -50.30 to -13.31; ten studies; Fig 3. Forest plot of interventions vs controls in opioid dose reduction in ten studies). However, considerable heterogeneity was noted (I² = 91.14%, 95%CI: 80.4% to 96.0%, p=0.00; Fig 3). A sensitivity analysis was conducted to investigate the source of heterogeneity and the Mehl-Madrone et al. (2016)'s study [34] was identified as an outlier (Fig 4. Sensitivity analysis of included studies). Upon its removal, the heterogeneity decreased from high ($l^2 = 91.14\%$) to medium ($l^2 = 1.14\%$) to medium ($l^2 = 1.14\%$) 59.41%), but the significance or direction of the pooled effects in our meta-analyses remained unchanged (MD: -24.88 mg; 95%Cl: -36.40 to -13.36; nine studies; Fig 5. Forest plot of interventions vs controls in opioid dose reduction in nine studies). Furthermore, a multivariable meta-regression analysis was conducted, revealing that heterogeneity could be partially explained by differences in the longest follow-up time across studies (p=0.014). Within the four RCTs [28, 29, 31, 32] provided data that enabled the pooled calculation of change for opioid reduction among 181 participants receiving different interventions compared to 162 receiving usual care (MD: -24.40 mg; 95%CI: -36.32 to -12.47; $I^2 =$ 9.21%, p=0.35; Fig 6. Forest plot of interventions vs controls in opioid dose reduction in four RCTs), a subgroup meta-analysis of two trials [28, 29] using the MORE protocol (mindfulness) found a significant reduction in opioid dosage in 84 patients receiving this intervention, compared to 77 having supportive care (MD: -29.36 mg; 95%CI: -40.55 to -18.17; I² = 0.00%, p=0.37; Fig 6). Similar decreases in opioid dose were reported by Wartko et al. (2023) [32] and Sullivan et al. (2017) [31] using CBT-based multicomponent interventions. However, no between-group statistical significance was attained (MD: -10.10 mg; 95%CI: -33.61 to 13.40; $l^2 = 0.00\%$, p=0.52; Fig 6).

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

Within the six cohort studies [33-38], where various interventions were implemented, a significant decrease in the use of opioid medications was observed in the intervention groups (MD: -29.89 mg; 95%Cl: -49.00 to -10.78; $I^2 = 72.72\%$, p=0.01; Fig 7. Forest plot of interventions vs controls in opioid dose reduction in five cohort studies). Subgroup analysis of Oldfield et al. (2018) and Seal et al. (2021) using CBT-based interventions showed a significant reduction in opioid dose, compared to those in the control group. (MD: -41.68 mg; 95%Cl: -58.47 to -24.89; $I^2 = 0.00\%$, p=0.76; Fig 7). **Opioid cessation** No significant differences were observed in opioid cessation (Odds ratio: 1.55, 95%CI: 0.3 to 2.81; I2=50.79%, p=0.13; three studies; Fig 8. Forest plot of interventions vs controls in opioid cessation) between intervention groups and controls. In the two RCTs [30, 31], although the interventions had slight variations, both studies implemented a weekly 10% dose reduction protocol combined with education and consultation as core components of the interventions. In the Sandhu et al. (2023) study [30], patients undergoing skill-based learning and education had a significantly higher cessation rate than those receiving usual care (Odds radio [OR]: 5.23; 95% CI 2.87 to 9.52; Fig 8.). However, pooled meta-analysis showed no statistically significant change in opioid discontinuation (OR: 1.10; 95%CI -0.48 to 2.67; Fig 8.). Moderate heterogeneity (I²=58.59%, 95% CI 0% to 86.2%) was observed, primarily attributed to the small sample size of the Sullivan et al. (2017) study [31]. In the cohort study [38] reporting opioid cessation, where 37 patients received cannabis-assisted opioid replacement along with patient education. Among them, 15 patients completely discontinued the opioid use over a period of 21 months. When compared to a control group receiving education alone, the cessation rate of opioid was lower in the control group, with only 1 out of 29 patients achieving opioid cessation;

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

however, this difference was not statistically significant, primarily because of the very small sample size (OR: 2.95, 95% CI 0.85 to 5.05; Fig 8). Pain severity Pain severity changes at different observation time points were reported in three trials [30-32], all utilizing interventions grounded in behavior change and patient education. Due to the variations in pain severity measurements across studies, standard mean differences were used for pooling the estimates. While a decrease in pain severity was observed in all three trials, the between-group difference was small and non-significant (SMD -0.13; 95% CI -0.37 to 0.11, I^2 =33.51%, p=0.22; Fig 9. Forest plot of interventions vs controls in pain severity improvement). It is worth noting that this 0.13point reduction in pain score might not have meaningful clinical implications. Due to the poor study quality and high heterogeneity, meta-analysis was not feasible for two cohort studies [35, 38] reporting the outcome of pain severity. Therefore, the results were narratively reviewed. Compared with these behavioral, psychological and physical interventions, the pharmacological intervention (cannabis) combined with patient education, as used in the Vigil et al. (2017) study [38], showed a significant decrease in pain intensity score (MD: -3.4 on a scale of 0-10, p<0.001), which suggested a meaningful clinical implication. Acupuncture, as employed in the Montgomery et al. (2020) study [35], exhibited an immediate effect in alleviating pain (a reduction in pain intensity score of MD 1.3 on a scale of 0-10, p<0.01). However, there were no significant differences after 9 months (p = 0.15), indicating acupuncture's short-term effects. Adverse events Adverse events (AEs) were infrequently examined in included studies, with the majority of reported AEs being associated with psychological and nervous system effects. In Wartko et al. (2023)'s study [32], which involved 79 participants receiving CBT-based pain coping skills training plus usual care, six cases of increased pain, one case of withdrawal symptoms, and one case of anxiety were noted. No serious adverse events (SAEs) were documented in this study. In Sandhu et al. (2023) [30], adverse events such as sleep disturbance, suicidal ideation, headache, withdrawal symptoms were reported by 22 of 305 participants (7%) and 8 of 303 participants (3%), in the intervention and usual care groups, respectively. SAEs occurred in 8% (25/305) of the participants in the intervention group and 5% (16/303) in the usual care group, with the most common SAEs being gastrointestinal disorder, metastatic cancer, hospitalization due to increased pain, and unknown cause of death.

Discussion

Summary of main findings

In this systematic review and meta-analysis, we examined 11 studies (five RCTs and six cohort studies) assessing the effectiveness of opioid reduction interventions for patients with CNCP in primary healthcare settings. Despite methodological differences, both RCTs and observational studies yielded statistically similar results, allowing for the pooling of results across the full range of eligible studies. Overall, intervention groups exhibited significant reductions in opioid dosage compared to usual care or active control. Subgroup analyses revealed significant opioid dose reductions with mindfulness and CBT-based multimodalities, respectively, compared to usual care. No significant differences were observed in opioid cessation or pain severity. Adverse events were infrequently examined, with withdrawal symptoms commonly reported. Medium heterogeneity was observed across all studies for each outcome, likely stemming from variability in interventions, follow-up durations, and healthcare providers involved. Nevertheless, the I² values for subgroup analyses were low.

Compare with existing literature

Our study conclusion generally aligns with previous systematic reviews [16-19] that the strength of evidence was insufficient to draw conclusions. However, our study extends these reviews by providing an updated and comprehensive assessment of the literature, adding one recent good-quality RCT. Supported by subgroup meta-analyses, we elucidated the effectiveness of mindfulness in reducing LTOT. Meanwhile, we highlighted key components such as CBT, patient education, mindfulness, exercise, which may contribute to the successful opioid reduction and thus merit consideration for future intervention development. Importantly, our study exclusively targeted primary care settings, distinguishing it from others that included secondary and tertiary care settings. Although de Kleijn et al. (2021) [17] solely focused on primary care settings, their results were narratively synthesized, and they included studies using simple opioid tapering protocols or interventions targeted at physicians.

Clinical guidelines [11, 12] recommend an initial reduction of opioid dosage by 10% per week, with adjustments for high-dose users (> MEDD 120 mg/day) or those on LTOT exceeding one year [39]. In our study, we observed a pooled mean opioid reduction of 24.88 mg/day from a baseline of 87.4 mg/day. Although this reduction was aggressive and exceeded the guideline-recommended reduction rate, it did yield a clinically meaningful decrease in opioid dosage without worsening pain severity. It is important to acknowledge that adherence to guideline recommendations does not necessarily guarantee optimal patient outcomes, as individual responses to opioid reduction strategies may vary. In fact, the primary goal of CNCP management is to maintain body function rather than achieve complete pain eradiation. Therefore, efforts should prioritize reducing opioids to minimize potential harms associated with LTOT. Meanwhile, despite limited examination of adverse events in this study, our findings align with existing evidence [40, 41], suggesting that opioid reduction may lead to withdrawal symptoms, increased pain severity, suicides or all-cause mortality.

Therefore, close monitoring of patient responses to opioid reduction strategies is essential for optimizing treatment outcomes while mitigating adverse effects.

Our findings highlighted the effectiveness of the MORE protocol, with mindfulness as its core component, in reducing opioid dose for CNCP patients in the short term (3 months). Additionally, meta-analytic results indicated a significant and strong association between mindfulness and pain reduction [42]. In another study [43] conducted by the same author using the MORE protocol, participants reported significantly greater improvements in psychological and physical function outcomes (e.g., general activity, mood, walking ability, normal work, relationships, sleep, and enjoyment of life.) compared to the support group during the three-month follow-up period. In view of this evidence, mindfulness could be considered a potential component in the development of opioid reduction strategies. However, before recommending widespread implementation of this intervention, further validation through replication in a second trial with a longer observation period (≥12 months) within primary care settings is necessary.

Contrary to expectations, CBT-based interventions did not show a significant reduction in opioid dosage in RCTs [31, 32]. This finding aligns with recent evidence from a recent cluster RCT, indicating that although CBT significantly reduced pain severity, it did not result in significant differences in opioid use between groups [43]. The reason for this non-significant result may be twofold. First, the small sample size and variations in interventions across studies may have contributed to the lack of statistical significance. Second, the study conducted by Sullivan et al. (2017) [31] involved high-dose users (207±245 mg/day), suggesting that behavior changes might not be superior to usual care in reducing opioids dosage for this population. However, the pain relief achieved through CBT may contribute to a subsequent decrease in opioid utilization, although this effect may take time to manifest. Two observational studies [36, 37]

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

employing similar CBT-based interventions reported significant reductions in opioid dosage compared to usual care. This inconsistency with findings from RCTs may be attributed to the variations in interventions. Additionally, observational studies may yield more promising results due to unadjusted confounders. Further investigation with long-term follow-up and larger sample sizes is warranted to elucidate the effects of CBT on opioid reduction.

Pharmacological interventions (cannabis-assisted opioid substitution) showed promising result, with a higher rate of opioid cessation and improved pain severity observed among the study population. This could be explained by the fact that patients often perceive pharmacotherapies as providing immediate pain relief, contrasting with non-pharmacological approaches which may require more time to yield noticeable effects. Consequently, patients may be more inclined towards pharmacological treatments, especially during episodes of exacerbated pain. This preference may be influenced by patients' desire to promptly alleviate pain [44], and the challenges associated with accessing non-pharmacological therapies [45], which further perpetuates the reliance on pharmacotherapy in managing CNCP symptoms. While cannabis demonstrates efficacy in replacing opioids for CNCP management, its longterm use may pose potential risks, including lower educational achievement, psychiatric illness, and residual cognitive impairment [46]. Therefore, careful consideration and monitoring are necessary when utilizing cannabis as a substitute for opioids in CNCP management.

Current clinical guidelines from the UK NICE (National Institute for Health and Care Excellence) [13, 47] and NHS Oxford Hospital [12] advocate for a holistic approach beyond pharmacotherapy alone. Our research findings align with these recommendations, revealing that a combination of cognitive change strategies, acupuncture, exercise, patient education and pharmacotherapies, delivered by a

multidisciplinary team were more effective in opioid reduction. Central to this success is the practice of shared decision making between patient and healthcare professionals. The collaboration among diverse healthcare professionals (GPs, nurses, therapists, pharmacists, etc) is crucial, as each contributes unique expertise and insights to the table. Nevertheless, challenges remain in accessing to multimodal cares, particularly for individuals unable to take time off work, those residing in regions with limited services, and individuals from culturally and linguistically diverse communities. Addressing these access barriers is essential to ensuring equitable healthcare delivery.

Strengths and limitations

To our knowledge, this is the first and most up-to-date systematic review and metaanalysis, to evaluate the effectiveness of interventions on opioid dose reduction and pain outcomes for patients with CNCP, with a particular emphasis on primary healthcare settings. By conducting a comprehensive literature search and including recently conducted studies in the UK, this research holds informative value for the potential implementation of interventions outside the US primary care settings. Moreover, several key subgroup analyses were conducted to identify which intervention (components) are effective in achieving opioid reduction purpose.

Our study also had several limitations. First, the relatively small number of included participants, short follow-up periods, and lack of blinding to interventions may have introduced biases and impacted the overall quality of the included studies. Second, data in observational studies were sourced from secondary databases or electronic medical records, which could cause information bias. Third, funnel plots and the Egger's test were not performed due to the small number of studies included in the meta-analyses Fourth, the majority of the studies were conducted on white populations in the US, likely influenced by the opioid crisis in that country, thus limited the generalizability of our research findings to other ethnicities and regions. Lastly, data

was insufficient to support meta-analyses of quality of life or function.

Conclusion

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

515

516

Although according to prior studies, no specific interventions can be recommended over one another, multidisciplinary opioid reduction strategies, incorporating components such as CBT, pain education, mindfulness, exercise and acupuncture, have demonstrated effectiveness and tolerability in reducing opioid doses and improving pain severity among patients with CNCP in primary care settings. However, robust evidence remains limited due to several factors, including a shortage of well-designed research studies, inadequate long-term follow-up periods and absence of QoL-related outcomes. Future studies should prioritize investigating the active components within these interventions to gain a deeper understanding of the specific strategies contributing to positive outcomes. Additionally, it is essential to assess the cost-effectiveness and patient acceptability of these interventions before their implementation in specific primary care contexts.

Acknowledgments

514 None.

Contributors

- 517 Conceptualization: LCC, EK, QC, TCC.
- 518 Data curation: QC, CG, TCC, EK.
- 519 Formal analysis: QC, EK.
- 520 Investigation: QC, CG, TCC.
- 521 Methodology: QC, EK.
- 522 Project administration: QC.
- 523 Supervision: EK TA CG LCC.
- 524 Validation: CG TCC.

525 Visualization: QC.

526 Writing – original draft: QC.

527 Writing – review & editing: QC CG TA TCC LCC EK.

529 Funding source

530 None.

References

- 1. Anekar, A.A. and M. Cascella, WHO analgesic ladder. 2020.
- 2. Boudreau, D., et al., *Trends in long-term opioid therapy for chronic non-cancer pain.* Pharmacoepidemiology and drug safety, 2009. **18**(12): p. 1166-1175.
- 3. Smolina, K., et al., *Patterns and trends in long-term opioid use for non-cancer pain in British Columbia*, 2005–2012. Canadian Journal of Public Health, 2016. **107**: p. e404-e409.
- 4. Werber, A., et al., *Opioid therapy in the treatment of chronic pain conditions in Germany.* Pain Physician, 2015. **18**(3): p. E323.
- 5. Kalkman, G., et al., *Practice variation in opioid prescribing for non-cancer pain in Dutch primary care: A retrospective database study.* Plos one, 2023. **18**(2): p. e0282222.
- Hansen, C.A., et al., Epidemiological Factors Associated with Prescription of Opioids for Chronic Non-Cancer Pain in Adults: A Country-Wide, Registry-Based Study in Denmark Spans 2004–2018. Journal of Pain Research, 2023: p. 463-485.
- 7. Jani, M., et al., *Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: a retrospective cohort study.* PLoS Medicine, 2020. **17**(10): p. e1003270.
- 8. Busse, J.W., et al., *Opioids for chronic noncancer pain: a systematic review and meta-analysis*. Jama, 2018. **320**(23): p. 2448-2460.
- 9. Gomes, T., et al., *The burden of opioid-related mortality in the United States*. JAMA network open, 2018. **1**(2): p. e180217-e180217.
- 10. Edlund, M.J., et al., Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug and alcohol dependence, 2010. **112**(1-2): p. 90-98.
- 11. Dowell, D., T.M. Haegerich, and R. Chou, *CDC guideline for prescribing opioids for chronic pain—United States, 2016.* Jama, 2016. **315**(15): p. 1624-1645.
- 12. NHS Oxford University Hospital. Guidance for opioid reduction in primary care. https://www.ouh.nhs.uk/services/referrals/pain/documents/gp-guidance-opioid-reduction.pdf [Accessed on 04 Feb 2024].
- 13. NICE. Chronic Pain, management. 2021. Available from: https://cks.nice.org.uk/topics/chronic-pain/management/management/. [cited on Feb 7th 2024].
- 14. Cross, A.J., et al., *Barriers and enablers to monitoring and deprescribing opioid analgesics for chronic non-cancer pain: a systematic review with qualitative evidence synthesis using the Theoretical Domains Framework.* BMJ Quality & Safety. 2022. **31**(5): p. 387-400.
- 15. Frank, J.W., et al., *Patients' perspectives on tapering of chronic opioid therapy: a qualitative study.* Pain medicine, 2016. **17**(10): p. 1838-1847.
- 16. Avery, N., et al., Efficacy of interventions to reduce long term opioid treatment for chronic non-cancer pain: systematic review and meta-analysis. Bmj, 2022. **377**.
- 17. de Kleijn, L., et al., *Opioid reduction for patients with chronic pain in primary care: systematic review.* British Journal of General Practice, 2022.
- 18. Frank, J.W., et al., *Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review.* Annals of internal medicine, 2017. **167**(3): p. 181-191.
- 19. Mathieson, S., et al., *Deprescribing opioids in chronic non-cancer pain: systematic review of randomised trials.* Drugs, 2020. **80**(15): p. 1563-1576.
- 20. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
- 21. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.* International Journal of Surgery, 2021. **88**: p. 105906.
- Sterne, J.A., et al., RoB 2: a revised tool for assessing risk of bias in randomised trials. bmj, 2019. 366.
- 23. Wells, G.A., et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000, Oxford.
- 24. Borenstein, M., et al., *A basic introduction to fixed-effect and random-effects models for meta -analysis*. Research synthesis methods, 2010. **1**(2): p. 97-111.
- 25. Higgins, J.P. and S. Green, Cochrane handbook for systematic reviews of interventions. 2008.
- 26. Kontopantelis, E., D.A. Springate, and D. Reeves, A re-analysis of the Cochrane Library data:

- the dangers of unobserved heterogeneity in meta-analyses. PloS one, 2013. 8(7): p. e69930.
- 27. Petropoulou, M. and D. Mavridis, *A comparison of 20 heterogeneity variance estimators in statistical synthesis of results from studies: a simulation study.* Statistics in medicine, 2017. **36**(27): p. 4266-4280.
- 28. Garland, E.L., et al., Mindfulness-oriented recovery enhancement reduces opioid dose in primary care by strengthening autonomic regulation during meditation. American Psychologist, 2020. **75**(6): p. 840.
- 29. Hudak, J., et al., Endogenous theta stimulation during meditation predicts reduced opioid dosing following treatment with Mindfulness-Oriented Recovery Enhancement. Neuropsychopharmacology, 2021. **46**(4): p. 836-843.
- 30. Sandhu, H.K., et al., Reducing opioid use for chronic pain with a group-based intervention: a randomized clinical trial. JAMA, 2023. **329**(20): p. 1745-1756.
- 31. Sullivan, M.D., et al., *Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial.* The journal of pain, 2017. **18**(3): p. 308-318.
- 32. Wartko, P.D., et al., STRategies to Improve Pain and Enjoy life (STRIPE): results of a pragmatic randomized trial of pain coping skills training and opioid medication taper guidance for patients on long-term opioid therapy. Pain, 2023.
- 33. Goodman, M.W., T.P. Guck, and R.M. Teply, *Dialing back opioids for chronic pain one conversation at a time.* J Fam Pract, 2018. **67**(12): p. 753-757.
- 34. Mehl-Madrona, L., B. Mainguy, and J. Plummer, *Integration of complementary and alternative medicine therapies into primary-care pain management for opiate reduction in a rural setting.*The Journal of Alternative and Complementary Medicine, 2016. **22**(8): p. 621-626.
- 35. Montgomery, A.D. and R. Ottenbacher, *Battlefield acupuncture for chronic pain management in patients on long-term opioid therapy.* Medical Acupuncture, 2020. **32**(1): p. 38-44.
- 36. Oldfield, B.J., et al., *Multimodal treatment options, including rotating to buprenorphine, within a multidisciplinary pain clinic for patients on risky opioid regimens: A quality improvement study.* Pain Medicine, 2018. **19**(suppl_1): p. S38-S45.
- 37. Seal, K.H., et al., Opioid reduction and risk mitigation in VA primary care: Outcomes from the integrated pain team initiative. Journal of general internal medicine, 2020. **35**: p. 1238-1244.
- 38. Vigil, J.M., et al., Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study. PloS one, 2017. **12**(11): p. e0187795.
- 39. Chou, R., et al., Best practices, research gaps, and future priorities to support tapering patients on long-term opioid therapy for chronic non-cancer pain in outpatient settings. NAM perspectives, 2020. **2020**.
- 40. Hallvik, S.E., et al., *Patient outcomes after opioid dose reduction among patients with chronic opioid therapy.* Pain, 2022. **163**(1): p. 83-90.
- 41. Metz, V.E., et al., *Prescription opioid dose reductions and potential adverse events: a multi-site observational cohort study in diverse US health systems.* Journal of general internal medicine, 2023: p. 1-8.
- 42. Garland, E.L., et al., *Mind-body therapies for opioid-treated pain: A systematic review and meta-analysis.* JAMA internal medicine, 2020. **180**(1): p. 91-105.
- 43. Garland, E.L., E. Thomas, and M.O. Howard, *Mindfulness-oriented recovery enhancement ameliorates the impact of pain on self-reported psychological and physical function among opioid-using chronic pain patients*. Journal of pain and symptom management, 2014. **48**(6): p. 1091-1099.
- 44. Lewis, P.J., *Uncomfortable Prescribing Decisions in Secondary Care*. 2007, The University of Manchester (United Kingdom): Ann Arbor. p. 302.
- 45. Elsharydah, A., J. Wu, and F.C. Li, *Decreasing waiting time for new patients at a community pain clinic.* Proc (Bayl Univ Med Cent), 2022. **35**(3): p. 315-318.
- 46. Iversen, L., *Long-term effects of exposure to cannabis*. Current opinion in Pharmacology, 2005. **5**(1): p. 69-72.
- 47. NICE. Analgesics. 2022. Available from: https://bnf.nice.org.uk/treatment-summaries/analgesics/. [Cited on 2024 Feb 7th].